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ABSTRAK
Tujuan: mengetahui perbandingan kadar asymmetric dimethylarginine (ADMA) antar-stadium 3, 4, 
dan 5 pasien penyakit ginjal kronik (PGK) non-dialisis di RSUD Dr. Soetomo Surabaya. Metode: penelitian 
potong lintang dilakukan di Instalasi Rawat Jalan Ginjal dan Hipertensi RSUD Dr. Soetomo mulai bulan 
Januari-Februari 2015. Stadium PGK ditentukan berdasarkan rumus perkiraan LFG menurut rumus MDRD 4 
variabel. Analisis statistik perbedaan kadar ADMA ketiga kelompok subyek menggunakan uji Anova satu arah. 
Hasil: sebanyak 75 subyek, terdiri atas masing-masing 25 pasien PGK Stadium 3, 4, dan 5 non-dialisis. 
Umur rerata pasien PGK stadium 3, stadium 4, dan stadium 5 non-dialisis masing-masing 57,12 tahun, 54,80 
tahun, dan 53,68 tahun. Rerata kadar ADMA pada kelompok stadium 3 adalah 0,62 (0,11) IU/mL, kelompok 
stadium 4 adalah 0,72 (0,16) IU/mL, dan kelompok stadium 5 adalah 0,73 (0,18) IU/mL. Terdapat perbedaan 
kadar ADMA secara bermakna (p=0,04) antar-stadium PGK, dengan perbedaan terbesar pada perbandingan 
kelompok stadium 3 dan 5. Kesimpulan: terdapat perbedaan kadar ADMA yang bermakna antar-stadium PGK 
dan semakin tinggi pada stadium PGK yang lebih tinggi.
Kata kunci: penyakit ginjal kronis, asymmetric dimethylarginine (ADMA), penyakit kardiovaskular.
ABSTRACT
Aim: to determine the differences of ADMA level between stages 3, 4, and 5 non-dialysis of chronic kidney 
disease (CKD) patients at Outpatient Nephrology Clinic, Dr. Soetomo Hospital. Methods: a cross-sectional 
study was conducted on stage 3, 4, and 5 non-dialysis CKD patients at Outpatient Nephrology Clinic, Dr. 
Soetomo Hospital, Surabaya from January to February 2015. Stages of CKD were determined based on GFR 
estimation according to 4-variable MDRD formula. Statistical analysis of differences in the levels of ADMA in 
three subject groups use one-way ANOVA test. Results: seventy-five patients were included in the study. Each 
group consisted of 25 patients stage 3, 4, and, 5 non-dialysis patients. Mean age of stage 3, stage 4, and stage 
5 non-dialysis CKD patients were respectively 57.12 years, 54.80 years and 53.68 years. The mean levels of 
ADMA in stage 3, stage 4, and 5 were 0.62 (0.11) IU/mL, 0.72 (0.16) IU/mL, and 0.73 (0.18) IU/mL respectively. 
Analysis of the differences between the groups showed significant differences in ADMA levels (p=0.04), with the 
highest difference between stage 3 and stage 5. Conclusion: comparison of ADMA levels showed significant 
differences between CKD stages and the level tends to be higher along with increase severity of CKD stages.
Keywords: chronic kidney disease, asymmetric dimethylarginine (ADMA), cardiovascular disease.
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INTRODUCTION
Cardiovascular  disease (CVD) and 
atherosclerotic complications are the most 
important causes of morbidity and mortality in 
patients with chronic kidney disease (CKD).1 
Some evidences of association between renal 
dysfunction and cardiovascular complications 
was first discovered in dialysis population, 
where the incidence of cardiovascular mortality 
was very high. It was also found in subjects 
with less severe impaired renal function.2 
Traditional risk factors and non-traditional 
risk factors such as inflammation, oxidative 
stress, endothelial dysfunction, coronary artery 
calcification, hyperhomocysteinemia, and 
immunosuppressants have been associated with 
accelerated atherosclerosis. Coronary artery 
disease (CAD) is  one of the primary types of 
CVD in patients with CKD. Atypical presentation 
of CAD in patients with CKD often leads to delay 
in diagnosis and treatment. The diagnostic value 
of baseline ECG is often limited by non-specific 
changes due to left ventricular hypertrophy 
and electrolyte disturbances. Furthermore, the 
outcomes of CAD are poorer in patients with 
CKD than non-CKD counterparts.3
Endothelial dysfunction is common in CKD 
patients. It is due to the reduced bioavailability of 
nitric oxide (NO). Nitric oxide has a protective 
role for the cardiovascular system because it 
inhibits vascular muscle cell proliferation, platelet 
aggregability, and the adhesion of monocytes to 
the endothelium. Asymmetrical dimethylarginine 
(ADMA) is an endogenous inhibitor of endothelial 
nitric oxide synthase (eNOS) which may contribute 
to endothelial dysfunction and may participate 
actively in development of atherogenesis in 
patients with end-stage renal disease. ADMA is in 
part excreted by the kidney, but this compound is 
mainly disposed by transformation into citrulline, 
a reaction driven by the enzyme diethyl-diamino-
hydrolase (DDAH). Diethyldiaminohydrolase is 
present within the endothelial cells and is very 
sensitive to oxidative stress. Oxidative stress is 
pervasive in ESRD, therefore, high ADMA in this 
condition may be the expression of the high rate 
of generation of oxidants.4
Studies have demonstrated that high ADMA 
is strongly associated with well established 
risk markers such as increased intima-media 
thickness in the carotid arteries and concentric left 
ventricular hypertrophy.5-8 ADMA predicts death 
and cardiovascular complications independently 
of other risk factors in end-stage renal disease 
(ESRD) patients.9 Therefore, measuring the 
plasma ADMA level may be important to 
determined the cardiovascular risk in patient 
with CKD and manage the atherosclerotic 
complication earlier.
Previous researches showed that in patients 
with mild to moderate CKD, ADMA level is 
inversely correlated with glomerular filtration rate 
(GFR) and is a strong predictor for the progression 
towards ESRD and death in CKD patients 
underwent coronary angiography.9,10 Study 
performed by Kielstein et al.11 meanwhile showed 
that plasma level of ADMA are not correlated with 
GFR. Another study showed that mean plasma 
ADMA levels were not significantly different 
in renal patients with normal GFR and mild 
reduction of GFR but were significantly higher 
with more advanced stages of renal failure.12 
However, most of the previous studies performed 
also in CKD patient with CVD comorbidity and 
traditional risk factors whereas the elevation of 
ADMA level might be related to the CVD rather 
than the severity of CKD. The previous studies 
also did not analyze the differences of the ADMA 
level according to the CKD stages. An estimated 
GFR below 60 ml/min/1.73 m2 is a risk factor for 
both new and recurrent cardiovascular disease in 
the general population and in people at increased 
risk for cardiovascular disease. In these patients, 
cardiovascular morbidity is more common than 
progression to kidney failure.13 We conducted this 
study to determine and analyze the differences 
of the ADMA level in CKD patient with GFR 
less than 60 ml/min/1.73 m2. Comparing the 
differences of ADMA level between stages of 
CKD especially in moderate to advanced stage 
could provide us information about which stadium 
should undergo early intensive evaluation and 
treatment of risk factors for cardiovascular 
disease.
METHODS
Cross-sectional study was conducted to 
examine ADMA levels at various CKD stages 
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at Outpatient Nephrology Clinic, Dr. Soetomo 
Hospital, Surabaya. Data collection was done 
from January to March 2015. The inclusion 
criteria were patients with CKD stage 3, 4, and 
5 non-dialysis aged 21-65 years, and agreed to 
participate in the study. The exclusion criterias 
were subjects with cigarette smoking, poorly 
controlled diabetes mellitus, uncontrolled 
hypertension, history of cardiovascular disease, 
multiple organ failure, presence of hepatic 
dysfunction, pregnant, and on antioxidant use 
since these condition influenced the ADMA 
level. We determined the sampel size by equation 
for unpaired numerical analytical study and 
the result was 25 in each group, so that the 
total sample in three groups comprised of 75 
patients.14 Sampling was done using retrieval 
technique with consecutive sampling system.
CKD stage classification was based on NFK-
KDOQI Guidelines in 2002 and the determination 
of the estimated glomerular filtration rate (eGFR) 
use the 4-variables modification of diet in renal 
disease (MDRD) formula.15 Patients with CKD 
stages 1 and 2 were not included because these 
groups were difficult to find in nephrology 
outpatient clinic. Non-dialysis stage 5 CKD 
patients in this study were patients with eGFR<15 
ml/min/m2 but not yet experiencing symptoms 
of uremia. Determination of ADMA use ADMA 
ELISA kit made by standardized laboratory. 
Concentration in the plasma was determined in 
units of µmol/L.16 Based on internal studies in 
healthy subjects, the average levels of ADMA 
was 0.45 µmol/l. Normal ADMA level ranges 
was average serum/plasma ± 2 SD = 0.45 ± 0.19 
µmol/l.17
All of the subjects who met the inclusion and 
exclusion criteria were recorded for demography 
and clinical characteristics which include age, 
gender, body mass index, blood pressure, history 
of antihypertensives (ACE-inhibitor, ARB) 
medications, and antidiabetic drugs (metformin, 
thiazolidinediones, insulin). Venous blood sampling 
was performed on each subject for examination of 
ADMA levels, BUN, and serum creatinine. All data 
collected were then analyzed with a statistical test 
to determine differences in ADMA levels between 
the three groups of samples.
Data processing was done by the program 
R version 3.2.18,19 The data were analyzed with 
descriptive statistics and presented in the form 
of a frequency distribution table. Statistical 
analysis of ADMA levels differences among the 
three groups of subjects used one-way ANOVA 
test when data distribution was normal and 
data variance was the same as well. Post hoc 
analysis is conducted when the result of ANOVA 
showed significant differences between at least 
two groups to determine the magnitude of the 
differences between each group.14
RESULTS
The total number of samples in this study 
were 75 patients with CKD who were divided into 
3 groups of stages, each consist of 25 patients. 
Demographic and clinical characteristics of the 
subjects are shown in Table 1. The mean age 
of the study subjects was 55.20 (8.16) years. 
Parameters of hemoglobin and albumin showed 
that the higher the CKD stage of the patients, the 
lower the average value obtained. 
Table 2 shows the average levels of ADMA 
between stage groups. Post Hoc analysis are 
shown in Table 3, in which there is the highest 
difference in stages 3 and 5, while the lowest 
difference was in stage 4 and 5.
DISCUSSION
CKD has become recognised as a key 
independent risk factor for CVD. It is now 
increasingly apparent that individuals are more 
likely to die from cardiovascular disease than 
to develop ESRD. Initial evidence indicating 
a relationship between renal dysfunction and 
adverse cardiovascular events become apparent 
in those on dialysis, where the number of CVD 
deaths was found to be raised.20 Furthermore, 
CVD in CKD patients, as the major cause 
of death, cannot be entirely explained by the 
traditional cardiovascular risk factors. It has 
been hypothesized that this excessive risk can 
be attributed, at least in part, to endothelial 
dysfunction and reduced bioavailability of nitric 
oxide (NO), which might play a pivotal role in the 
initiation and progression of atherosclerosis and 
might be a potential link between cardiovascular 
disease and CKD.9
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Table 1. Demography and clinical characteristics of the subjects
Characteristics Stage 3 (n=25) Stage 4 (n=25) Stage 5 non-dialysis (n=25)
Age (years), mean (SD) 57.12 (5.40) 54.80 (7.14) 53.68 (10.89)
Sex (male), n (%) 16 (64.0) 8 (32.0) 11 (44.0)
CKD Causes, n (%)
 - DM 6 (24.0) 10 (40.0) 10 (40.0)
 - Non-DM 19 (76.0) 15 (60.0) 15 (60.0)
Proteinuria degree, n (%)
 - +1 16 (64.0) 13 (52.0) 3 (12.0)
 - +2 7 (28.0) 8 (32.0) 11 (44.0)
 - +3 1 (4.0) 2 (8.0) 6 (24.0)
 - +4 1 (4.0) 2 (8.0) 5 (20.0)
Estimated GFR (mL/min/1.73m2), mean (SD) 40.34 (7.45) 22.22 (3.84) 10.55 (3.21)
Serum Creatinine (mg/dl), median (range) 1.73 (1.20-2.40) 2.68 (1.90-3.70) 5.79 (3.30-15.50)
Albumin (g/L), mean (SD) 4.54 (0.35) 4.23 (0.45) 4.09 (0.49)
Haemoglobin (g/dL), mean (SD) 12.92 (1.96) 11.30 (2.02) 10.13 (1.50)
DM, n (%)
 - Insulin use 0 (0.0) 3 (33.3) 5 (50.0)
 - Tiazolidindion use 0 (0.0) 2 (20.0) 1 (10.0)
 - Metformin use 0 (0.0) 0 (0.0) 0 (0.0)
Random Blood Glucose (mg/dl), mean (SD) 109.88 (34.45) 107.92 (29.44) 116.36 (32.37)
Hypertension, n (%)  
 - ACEI/ARB use 11 (44.0) 11 (44.0) 12 (48.0)
 - Non HT/ non ACEI/ARB 14 (56.0) 14 (56.0) 13 (52.0)
Systolic BP (mmHg), mean (SD) 133.16 (14.52) 131.44 (16.32) 139.72 (13.12)
Diastolic BP (mmHg), mean (SD) 80.04 (9.45) 75.68 (10.36) 74.48 (11.21)
Dyslipidemia, n (%)
 - Statin use 8 (32.0) 10 (40.0) 4 (16.0)
 - Non-dyslipidemia/ non-statin 17 (68.0) 15 (60.0) 21 (84.0)
LDL (mg/dl), mean (SD) 102.28 (28.71) 109.08 (29.48) 93.32 (28.23)
Table 2. ADMA level between CKD stages
CKD groups Total Mean (SD) p value
Stage 3 25 0.63 (0.11) 0.04
Stage 4 25 0.72 (0.16)
Stage 5 25 0.73 (0.18)
Table 3. Results of post-hoc analysis
Mean 
Difference
Min Max p value
Stage 4 vs 3 0.09 -0.01 0.19 0.10
Stage 5 vs 3 0.10 -0.00 0.20 0.06
Stage 4 vs 5 0.01 -0.09 0.11 0.97
Asymmetric dimethylarginine is inhibitor of 
endothelial NOS. In those with ESRD, ADMA 
has been independently associated with the 
intima-media thickness of the carotid artery and 
may predict its progression during a one-year 
follow-up period.4,6 In a cohort of hemodialysis 
patients, scientists found that plasma ADMA 
may be a strong and independent risk factor of 
total mortality and cardiovascular outcome.20 
Asymmetric dimethylarginine is thought to be 
significantly associated with the oxidative stress 
process through its inhibition of NO, and thus 
leading to endothelial dysfunction and vascular 
damageand plays a major role in potentiating 
atherosclerosis.4
Asymmetric dimethylarginine levels are 
markedly elevated in renal impairment. Several 
prospective studies showed association between 
ADMA and CKD progression. Each 0.1 µmol/l 
increase of ADMA may increase 47% progression 
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of CKD.12 A study in patients with type 1 diabetes 
and overt diabetic nephropathy showed that 
an ADMA level higher than the median was 
associated with a faster yearly decline in GFF and 
a greater risk of developing ESRD over a median 
follow-up of 11.3 years.21 A study in patients 
with type 2 diabetes (with normoalbuminuria or 
microalbuminuria) followed up over 5.2 years 
reported progression of diabetic nephropathy to 
a more advanced stage.22 Patients with ADMA 
levels above the median had a 2.7-fold higher risk 
of disease progression. Together, these studies 
provide strong evidence that increased ADMA 
levels are associated with progression of CKD.23
NO is synthesized by stereospecic oxidation 
of the terminal guanidino nitrogen of the 
amino acid L-arginine by the action of NOS. 
NO synthesis can be selectively inhibited by 
competitive blockade of the NOS active site with 
guanidino-substituted analogues of L-arginine 
such as ADMA. ADMA is released from proteins 
that have been post-translationally methylated, 
and subsequently hydrolysed. These proteins are 
largely found in the nucleolus and appear to be 
involved in RNA processing and transcriptional 
control. There are two types of enzymes that 
methylate arginine residues: protein arginine 
methyl-transferase type I (PRMT I) forms 
ADMA and LNMA, whereas PRMT II forms 
symmetric dimethylarginine (SDMA), that is 
a stereoisomer of ADMA, which has no direct 
inhibitory effect on NOS. ADMA is renally 
excreted to some extent, but the major metabolic 
pathway is degradation by the enzyme DDAH, 
which hydrolyses ADMA to dimethylamine and 
L-citrulline. There are two isoforms of DDAH: 
DDAH I is predominately found intissues that 
express neuronal NOS, whereas DDAH II is 
predominately found in tissues expressing 
endothelial NOS. The increased ADMA levels 
that inhibit NOS resulting in decreased NO 
levels, which has major adverse consequences 
for the kidney and might lead to progression of 
CKD.24-26
Genetic predisposition factors are associated 
with increased ADMA in CKD. Dimethylarginine 
dimethylaminohydrolase-2 gene variations and 
PMRT-1 gene polymorphism are associated with 
ADMA levels in hemodialysis patients.27 The 
decline in DDAH-2 enzyme activity may inhibit 
ADMA metabolism and PMRT-1 increased 
activity will lead to increased production of 
ADMA, so both have a role in the increase of 
ADMA in CKD.28
Altough ADMA level was found to be 
elevated in CKD, the correlation between 
ADMA level and GFR showed conflicting 
results. In this study it was found that there was 
a significant difference in the levels of ADMA 
between CKD stages, with the lowest level in 
CKD stage 3 and the highest level was in CKD 
stage 5 (p=0.04). Post hoc analysis showed that 
the highest difference between two groups was 
found in the comparison of CKD stages 3 and 5, 
while the least difference was in the comparison 
between CKD stage 4 and 5. A study conducted 
by Ronden RA et al29 examined the decline in 
renal clearance and increased plasma ADMA 
levels in hypertensive subjects with mild to 
moderate renal insufficiency. The results of this 
study showed similar trends with our study, but 
the ADMA level for eGFR group 30-59 was 
lower than ADMA level in group stages 3 and 4 
in our study. The difference is probably because 
the subjects included in Ronden’s study were 
hypertensive patients, instead of CKD patients 
as in our study. Another explanation is that there 
is difference in ADMA measurement methods. 
Another study conducted by Eloot, et al which 
aims to determine whether the value of eGFR 
describes uremic toxins, including ADMA 
concentrations, at various stages of CKD, also 
showed similar results with our research.30
Previous studies showed that in patients with 
mild to advanced CKD, ADMA level is inversely 
correlated with GFR and it is a strong predictor 
for the progression towards ESRD and death.9,10 
A study conducted by Kielstein et al.11 showed 
that levels of ADMA increased independently of 
renal function in patients with CKD and did not 
correlate with GFR. Other studies in patients with 
mild to moderate kidney disease (GFR 30-90) 
indicates that the decline in GFR is associated 
with increased ADMA levels, but decrease in 
clearance of plasma ADMA is not associated 
with increased ADMA levels.29 Our study results 
showed that there was narrow differences of 
ADMA level in CKD stage 4 and 5 while in CKD 
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stage 3 and 4 had wider differences. This suggest 
that ADMA level started to increased in patient 
with mild to moderate CKD and reach the highest 
level in ESRD. However, in advanced CKD the 
elevation are not always correlate with GFR. This 
also suggest that there may be other mechanisms 
besides the influence of GFR that plays a role in 
ADMA accumulation in CKD.
However, our study has several limitations. 
The staging of CKD was based on estimated 
GFR instead of measured GFR and conducted 
only in one time measurement. We did not 
involve all CKD stages in our study, so that the 
pattern of ADMA accumulation in all stages 
could not be analyzed. The causes of CKD was 
only distinguished by DM and non-DM, whereas 
other causes of CKD, such as stones, infections, 
and autoimmune diseases, were not detailed. 
Some confounding variables were obtained only 
from very subjective history taking.
CONCLUSION
The mean level of ADMA in group stages 
3, 4 and 5 were respectively 0,63 µmol/L, 0.72 
µmol/L and 0.73 µmol/L. There were differences 
in ADMA level between CKD stages and ADMA 
levels increase along with the higher stage of 
CKD. The greatest increase in ADMA levels was 
between CKD stage 3 and stage 4, so that any 
attempt to reduce cardiovascular complications 
should be done at the time or before it reaches 
stage 3.
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